Aridis Pharmaceuticals (Aridis Pharmaceuticals) EBIT per Share : $-0.19 (TTM As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Aridis Pharmaceuticals EBIT per Share?

Aridis Pharmaceuticals's EBIT per Share for the three months ended in Sep. 2023 was $-0.02. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.19.

During the past 3 years, the average EBIT per Share Growth Rate was 22.60% per year. During the past 5 years, the average EBIT per Share Growth Rate was 13.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Aridis Pharmaceuticals's EBIT per Share or its related term are showing as below:

ARDS' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -51 Med: 11.7 Max: 23.2
Current: 22.6

During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Aridis Pharmaceuticals was 23.20% per year. The lowest was -51.00% per year. And the median was 11.70% per year.

ARDS's 3-Year EBIT Growth Rate is ranked better than
73.35% of 1302 companies
in the Biotechnology industry
Industry Median: 3.6 vs ARDS: 22.60

Aridis Pharmaceuticals's EBIT for the three months ended in Sep. 2023 was $-0.87 Mil.

Aridis Pharmaceuticals EBIT per Share Historical Data

The historical data trend for Aridis Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aridis Pharmaceuticals EBIT per Share Chart

Aridis Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT per Share

Get a 7-Day Free Trial

-7.66

-3.44

-2.44

-3.48

-1.60

Aridis Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EBIT per Share	Get a 7-Day Free Trial															-0.42	-0.34	-0.21	0.37	-0.02

Aridis Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Aridis Pharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2022 is calculated as

	EBIT per Share		(A: Dec. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-29.993	/	18.777
=	-1.60

Aridis Pharmaceuticals's EBIT per Share for the quarter that ended in Sep. 2023 is calculated as

	EBIT per Share		(Q: Sep. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.869	/	37.429
=	-0.02

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.19

Aridis Pharmaceuticals (OTCPK:ARDS) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Aridis Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of Aridis Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Aridis Pharmaceuticals (Aridis Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aridis Pharmaceuticals Inc (OTCPK:ARDS) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

983 University Avenue, Building B, Los Gatos, CA, USA, 95032

Website

https://www.aridispharma.com

Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.

Executives

Fibrosis Foundation Cystic	10 percent owner	4550 MONTGOMERY STREET, SUITE 1100N, BETHESDA MD 20814
Hasan Jafri	officer: Chief Medical Officer	5941 OPTICAL COURT, SAN JOSE CA 95138
Vu Truong	director, 10 percent owner, officer: CEO, CSO, Director	5941 OPTICAL CT., SAN JOSE CA 95138
Eric Patzer	director, 10 percent owner	5941 OPTICAL CT., SAN JOSE CA 95138
John F Hamilton	director	1360 O'BRIEN DR, MENLO PARK CA 94025
Michael Adrian Nazak	officer: Chief Financial Officer	5941 OPTICAL COURT, SAN JOSE CA 95138
Susan Richards Windham-bannister	director	78 BLANCHARD ROAD, BURLINGTON MA 01803
Isaac Blech	director	C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Fred Kurland	officer: Chief Financial Officer	C/O GENITOPE CORP, 525 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Wolfgang Dummer	officer: Chief Medical Officer	5491 OPTICAL CT., SAN JOSE CA 95138
Robert R Ruffolo	director
Shawn Lu	director	C/O CANTEX PHARMACEUTICALS, INC., 1792 BELL TOWER LANE, WESTON FL 33326
Robert K. Coughlin	director	5941 OPTICAL CT., SAN JOSE CA 95138
Craig S Gibbs	director	C/O FORTY SEVEN, INC., 1490 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025